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Abstract; 
Background; This study was carried out to determine the role of total serum alkaline Phosphatase in bone 
metastasis among patients of breast cancer. Study setting; Department of Surgery, Nishtar Medical University, 
Multan in collaboration with breast clinic MINAR. Study Duration; January 2016 to June 2017 Subjects and 
methods; It was a retrospective study carried out at breast clinic MINAR, Multan. The medical record of the 
female patients having breast cancer aged 25 to 70 years (who presented from January 2016 to June 2017) was 
scrutinized. All the registered patients during above mentioned period having breast carcinoma with metastatic 
bone disease, as depicted on bone scan, were taken as index cases. All the cases underwent total serum alkaline 
Phosphatase estimation. We collected 86 cases for this research study. Primary bone tumours, lymphomas, 
sarcomas and bone metastasis due to other primary visceral malignancies were excluded. All the required data 
were entered and analyzed using computer program SPSS version 20.0. Results; The mean age of the breast 
cancer patients was 46.51 ± 11.11 years (ranging from 25 – 70 years).  Eighty four (97.7%) were married. All the 
patients presented with lump breast. Only 3 (3.5%) of the cases gave family history of breast cancer and history 
of contraceptive pills was positive in 4 (3.7%) of the cases. History of breast feeding was positive in 63 (73.3%) 
of the cases. Mean age at menarche was 13.21± 0.896 years in our study cases. Mean age at menopause in our 
study was 46.86 ± 5.66 years. Total serum alkaline Phosphatase was raised in 27 (31.4%) cases. Only 6 (6.9%) 
of the cases showed its level more than 500 IU/L. Conclusion; Our study results don’t favor total serum alkaline 
Phosphatase estimation as biological marker of bone metastasis among breast cancer patients. Bone scan is more 
reliable and hence be employed for detection of bone metastasis. Further studies on bone ALP and total ALP 
estimation are required to generate further evidence on this subject. 
Keywords; Serum alkaline Phosphatase, breast cancer, bone metastasis.  
 
Introduction 
Breast cancer is the commonest cancer among females globally as well as nationally. It is the leading cause of 
cancer deaths in women1,2. Breast cancer accounts for 22% of all female cancers worldwide and approximately 
42% cases occur in the developing countries
6
. In USA, it has been found that 60% of patients have benign breast 
disease and 10% have malignancy 
7
. In Pakistan, a study carried out in 2001 reported a very low incidence of 
breast cancer (6%)
8
, while another study in 2003 reported a frequency of 24.2%. A study from Karachi, at Jinnah 
Postgraduate Medical Centre, in 2005 showed that 30% of malignancies among females occur in the breast9. 
There is also geographic variation, with the standardized age incidence rate being lower in developing than 
industrialized countries.
10 
The new millenniums still find breast cancer as a leading cause of cancer related death 
among females. It is expected that the number of new cases may rise to 15 million by 2025, with 60% of the 
cases occurring in developing countries 9. The disease occurs commonly among females but may also occur very 
less frequently in males
3, 4
. It is seen that if 100 female patients present with breast complaints, then among them 
30% may have no breast lesion, 40% may have fibrocystic changes, 7% may have benign tumor and 10% may 
have carcinoma.
5, 10 
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Breast carcinoma spreads either regionally (to regional lymph nodes) or systemically. It most frequently 
metastasizes to bones in addition to lung, liver and brain 
11
, 
12
,
 13.  
For staging and for therapeutic options for breast carcinoma it is necessary to detect the bone metastasis in these 
cases. Various tests are used to detect bone metastasis and simplest of all is total serum alkaline Phosphatase 
estimation. It is also raised in obstructive hepato-billiary disease, bone fractures, pregnancy, in growing children 
and even in old age. Some of these conditions are ruled out on history and some by other parallel tests like 
estimation of gama GT, bone Skiagrams and liver ultrasonography. The gold standard test for bone metastatis 
detection is bone scan, however  total serum alkaline Phosphatase is still being used as basic test for prediction 
of bone metastasis in some countries. If it is raised two times above normal or more than this, it is taken as 
abnormal and points towards some pathology. In patients of carcinoma breast its raised level points to some 
bony involvement and 14 levels above 500 IU/L raises the possibility of bone mets15, however may remain even 
normal in some cases of breast cancer with metastatic bone disease 16. The same trend was observed at our breast 
clinic during the evaluation of breast cancer patients.  So the present study was carried out to detect the 
significance of total Serum Alkaline Phosphatase estimation in prediction for bone metastasis in patients of 
breast carcinoma at a tertiary care hospital. 
Subjects and Methods:- 
It was a retrospective study carried out at breast clinic MINAR, Multan. The medical record of the female 
patients having breast cancer aged 25 to 70 years (who presented from January 2016 to June 2017) was 
scrutinized. All the registered patients during above mentioned period having breast carcinoma with metastatic 
bone disease, as depicted on bone scan were taken as index cases. All the patients also underwent total serum 
alkaline Phosphatase estimation. We collected 86 cases for this research study. Primary bone tumours, 
lymphomas, sarcomas and bone metastasis due to other primary visceral malignancies were excluded. All the 
required data was entered and analyzed using computer program SPSS version 20.0. 
Results; 
We examined medical record of 86 index cases. The mean age of the breast cancer patients was 46.51 ± 11.11 
years (ranging from 25 – 70 years).  Eighty four (97.7%) were married. All the patients presented with lump 
breast. Only 3 (3.5%) of the cases gave family history of breast cancer and history of contraceptive pills was 
positive in 4 (3.7%) of the cases. History of breast feeding was positive in 63 (73.3%) of the cases. Mean age at 
menarche was 13.21± 0.896 years in our study cases. Mean age at menopause in our study was 46.86 ± 5.66 
years. Total serum alkaline Phosphatase was raised in 27 (31.4%) cases. Only 6 (6.9%) of the cases showed its 
level more than 500 IU/L.  
 
Discussion; 
Breast carcinoma starts from the breast tissue at cellular level. The cells lining the ducts, tubules or any other 
tissue in the breast may develop malignant change and lead to carcinoma of breast. The malignant cell 
proliferates into a group of cancer cells that can grow locally and invade the surrounding tissues or spread 
(metastasize) to distant areas of the body. Bone metastases are common in breast cancer and develop in 
approximately 70 % of patients with metastatic breast cancer. 
In our study, mean age of the patients was 46.51 ± 11.11 years (range; 25 – 70 years). Similar results 
have been reported by various researchers from Pakistan showing prevalence of the disease in middle of 4th 
decade of their life. Memon et al 
17
 from Karachi reported 47.8 ± 12.4 years mean age of women with breast 
cancer. Another study 
18
 from Karachi reported 47.5 ± 12.1 years mean age of patients presenting with breast 
cancer. The findings of both these studies are close to that of our study. Similar findings have been reported by 
Nazir et al 
19
 and Nisar et al 
20
. 
In our study family history of breast cancer was positive 3.5 % which is quite less than that reported from other 
studies in Pakistan. A study conducted by Memon et al 
17
 from Karachi reported 13.3 % positive family history. 
Another study from Karachi 18  reported 20 % patients of breast cancer had positive family history. The same 
figures have been reported by Faheem et al 
 21 
.  A study by de Bruin MA et al 
22
 reported as high as 50 % family 
history of breast cancer in Asian women. The different findings may be due to differences in cultural, social, 
lifestyle and living standards. Moreover females in our study may be more shy, less responsive to the data 
collector and less educated. Lack of awareness about this disease entity may be another possible reason.  
History of breast feeding was positive in 73.3 % in our study cases. Various studies have reported history of 
breast feeding differently, in some studies it is 61 % and in another study 42 % Memon et al 
17
 and de Bruin MA 
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et al 
22
 respectively. These differences may be again due to cultural variations. Moreover, our study patients were 
house-wives and jobless and from poor socioeconomic status, so they were unable to afford formula milks.  
Mean age at menarche was 13.21± 0.896 years in our study cases while Memon et al 17 from Karachi reported 
12.96±1.60 years mean age at menarche. The same findings have been reported by Nazir et al 19. These both 
findings are in consonance with our study results.  
Mean age at menopause in our study was 46.86 ± 5.66 years which is in compliance with other studies conducted 
by Memon et al 17 from Karachi who reported 46.35 ± 6.65 years mean age of the ladies with breast cancer.  
Alkaline Phosphatases and its various iso-enzymes are phosphatidylinositol anchored cell membrane proteins. 
Raised serum ALP has various clinical implications. It is raised in various conditions like intra and extra hepatic 
billiary obstruction, infiltrative liver disease, bone mets and cancers. ALP estimation is an inexpensive and is 
used in various developing countries as a potential biological marker. In some studies on breast cancer its 
parallel rise with advancing disease has been noted 23 . In our study, total serum alkaline phosphatase level was 
raised in 31.4% of patients while its level more than 500 IU/L was noted in 6.9 %. 
In a study conducted by Singh et al 
23
 its level  more than 500 IU/L have been reported in 61 % of the patients in 
stage 4 of breast carcinoma cases and its rise strongly relates to bone mets. Singh et al 23 further stated that 
progressive increase in ALP is an indication of bone metastasis in breast cancer patients. Mayne et al 24 also 
reported increase in total alkaline phosphatase in 20 % of patients with breast cancer.  
Sandhya et al 
25
 reported a significant rise to 6 fold of ALP normal levels in metastatic patients with breast 
carcinoma. The findings of our study are not in agreement with the study conducted by Singh et al 23 and 
Sandhya et al 
25
 , it may be due to the reason that the patients in our study may not have so advanced disease. 
Total ALP may be useful diagnostic tool in monitoring the activity of the disease where sophisticated tools are 
not readily available moreover its estimation is simple and cost-effective but its significance in detection of bone 
mets remains controversial. 
With the recent advent of more specific immune-assays like bone ALP estimation has gained clinical interest and 
several studies have indicated that in certain situations bone ALP might provide better index of bone formation 
than measurement of total ALP. They also reported that bone ALP was more frequently raised in bone metastatic 
disease of prostatic cancer patients compared to the patients of breast cancer or lung cancer with bone mets. So, 
bone alkaline Phosphatase estimation might have provided better picture  on this subject than total ALP but this 
test was not available in our setting so total serum alkaline Phosphatase was estimated in our study cases.  
 
Conclusion; 
Our study results don’t favor total serum alkaline Phosphatase estimation as biological marker of bone metastasis 
among breast cancer patients. Bone scan is more reliable and hence be employed for detection of bone metastasis. 
Further studies on bone ALP and total ALP estimation are required to generate further evidence on this subject.  
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